Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Shire Plc Ads (SHPG)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 53,370,580
  • Shares Outstanding, K 303,950
  • Annual Sales, $ 15,161 M
  • Annual Income, $ 4,272 M
  • 36-Month Beta 1.02
  • Price/Sales 3.59
  • Price/Cash Flow 7.88
  • Price/Book 1.46

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate 3.81
  • Number of Estimates 8
  • High Estimate 3.94
  • Low Estimate 3.67
  • Prior Year 3.98
  • Growth Rate Est. (year over year) -4.27%

Price Performance

See More
Period Period Low Period High Performance
1-Month
167.75 +5.20%
on 10/25/18
182.47 -3.29%
on 11/12/18
+1.46 (+0.83%)
since 10/19/18
3-Month
165.61 +6.55%
on 09/07/18
182.47 -3.29%
on 11/12/18
+6.04 (+3.55%)
since 08/17/18
52-Week
123.73 +42.62%
on 02/09/18
182.47 -3.29%
on 11/12/18
+29.10 (+19.74%)
since 11/17/17

Most Recent Stories

More News
Shire's Filing Accepted by FDA for Gattex's Label Expansion

The FDA accepts Shire's (SHPG) sNDA and is expected to take action in March 2019.

LLY : 115.23 (+1.23%)
SHPG : 176.67 (+0.62%)
PFE : 43.92 (+0.94%)
BMY : 53.26 (-1.50%)
Takeda Announces Publication of Circular and Notice of Extraordinary General Meeting of Shareholders in Relation to the Proposed Acquisition of Shire

Further to the announcement on May 8, 2018, by Takeda Pharmaceutical Company Limited ("Takeda" or the "Company") regarding the proposed acquisition (the "Acquisition") of Shire plc ("Shire"),...

SHPG : 176.67 (+0.62%)
Publication of Scheme Document

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION...

SHPG : 176.67 (+0.62%)
Merrimack (MACK) Suffers Wider-Than-Expected Loss in Q3

Merrimack (MACK) discourages with Q3 loss, falling shy of estimates as well as deteriorates from the year-ago quarter's figure. Also, the company fails to reap any revenues in the period.

AZN : 40.71 (+0.10%)
SHPG : 176.67 (+0.62%)
SNY : 44.83 (-0.60%)
MACK : 4.57 (+1.11%)
Shire's (SHPG) Earnings, Revenues Miss Estimates in Q3

Shire (SHPG) misses earnings and revenue estimates in the third quarter of 2018. The company completes the sale of its Oncology franchise in the quarter.

MRK : 76.00 (-0.08%)
LLY : 115.23 (+1.23%)
SHPG : 176.67 (+0.62%)
BMY : 53.26 (-1.50%)
Shire: 3Q Earnings Snapshot

DUBLIN (AP) _ Shire PLC (SHPG) on Thursday reported third-quarter profit of $537.2 million.

SHP.LS : 4,563.000 (-1.26%)
SHPG : 176.67 (+0.62%)
Takeda Comments on Ongoing Phase 1 Review by the European Commission of the Proposed Acquisition of Shire plc

Takeda Pharmaceutical Company Limited (TSE: 4502) ("Takeda") today issued the following statement with regard to its discussions with the European Commission ("EC") as part of its Phase 1...

SHPG : 176.67 (+0.62%)
TKPYY : 19.4300 (+2.64%)
Shire Files Submission for U.S. FDA Approval to Manufacture FLEXBUMIN(R) at New Plasma Manufacturing Facility near Covington, Georgia

Intended audience: global

SHPG : 176.67 (+0.62%)
Shire plc: CHMP Recommends EU Marketing Authorisation of lanadelumab for the Prevention of HAE Attacks

CHMP Recommends EU Marketing Authorisation of lanadelumab for the Prevention of HAE Attacks

SHPG : 176.67 (+0.62%)
Takeda Receives Clearance from the Japan Fair Trade Commission for the Proposed Acquisition of Shire plc

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION...

SHPG : 176.67 (+0.62%)
TKPYY : 19.4300 (+2.64%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More Share

Trade SHPG with:

Business Summary

Shire Pharmaceuticals Group plc is a specialty pharmaceutical company focused primarily on two therapeutic areas: central nervous system disorders and metabolic bone diseases. (press release)

See More

Key Turning Points

2nd Resistance Point 177.62
1st Resistance Point 176.61
Last Price 176.67
1st Support Level 174.79
2nd Support Level 173.98

See More

52-Week High 182.47
Last Price 176.67
Fibonacci 61.8% 160.03
Fibonacci 50% 153.10
Fibonacci 38.2% 146.17
52-Week Low 123.73

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar